Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

  • Read more about Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19

  • Read more about Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19

TME Pharma

By jpalfreyman on Wed, 04/03/2024 - 09:55
  • Read more about TME Pharma

RemeGen Co., LTD.

By jpalfreyman on Wed, 04/03/2024 - 09:48
  • Read more about RemeGen Co., LTD.

Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients

  • Read more about Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients

SLV213 Treatment in Ambulatory COVID-19 Patients

  • Read more about SLV213 Treatment in Ambulatory COVID-19 Patients

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

  • Read more about To Evaluate SSD8432/Ritonavir in Adults With COVID-19

Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

  • Read more about Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

  • Read more about Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

  • Read more about Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 72
  • Page 73
  • Page 74
  • Page 75
  • Current page 76
  • Page 77
  • Page 78
  • Page 79
  • Page 80
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA